Organization
ANRS, Emerging Infectious Diseases
23 clinical trials
Clinical trial
Interventional, Multicenter, Open-label, Randomized, Non-comparative Trial Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV VirusesStatus: Not yet recruiting, Estimated PCD: 2027-02-28
Clinical trial
The Yellow Fever Vaccine Immunity in HIV Infected Patients: Studies of Immunological Responses at 10 Years (ANRS 0146s NovaaTen)Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized Controlled Trial to Evaluate the Efficacy, Acceptability and Safety of Event-driven Pre-exposure Prophylaxis for HIV Using TAF/FTC in Men Who Have Sex With Men in Thailand and FranceStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase III, Open-label, Randomized, Multicenter Trial EvaLuating the Non-inferiority of DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionStatus: Not yet recruiting, Estimated PCD: 2026-04-01
Clinical trial
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the OPTICOV StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, VietnamStatus: Completed, Estimated PCD: 2020-11-30
Clinical trial
A Pilot Open Label Phase I Trial to Evaluate the Safety and the Tolerability of a Combination of Two HIV-1 Inducers in HIV+ Sub-type B Patients Under cART With Undetectable Viral LoadStatus: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
Impact of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis Persistence and Coverage in Men Who Have Sex With Men in France: a Randomized Controlled Clinical Trial.Status: Not yet recruiting, Estimated PCD: 2025-10-30
Clinical trial
A Phase 1/2 Multicenter, Randomized Study of the Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of VaccineStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) or Dolutegravir + Lamivudine + Tenofovir (DTG+3TC+TDF) in West and Central African HIV-1 Infected PatientsStatus: Active (not recruiting), Estimated PCD: 2025-02-05
Clinical trial
Access to Pre-exposure Prophylaxis for Men Who Have Sex With Men: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)Status: Completed, Estimated PCD: 2020-12-23
Clinical trial
EHVA P01/ANRS VRI08: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected AdultsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Randomised Phase II Placebo-controlled Trial of Antiretroviral Therapy (ART) Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo During Primary HIV-1 Infection to Study the Impact on Post-treatment HIV Control.Status: Recruiting, Estimated PCD: 2026-12-10
Clinical trial
Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological MechanismsStatus: Recruiting, Estimated PCD: 2025-08-30
Clinical trial
Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)Status: Active (not recruiting), Estimated PCD: 2023-02-19
Clinical trial
EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic InfectionStatus: Completed, Estimated PCD: 2023-07-12
Clinical trial
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)Status: Recruiting, Estimated PCD: 2023-08-01
Clinical trial
Phase II Trial Evaluating the Immunogenicity and Safety of Ad26.COV2.S Vaccine in Adult Participants in MaliStatus: Active (not recruiting), Estimated PCD: 2022-09-25
Clinical trial
Pilot Therapeutic Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Trial Evaluating the Immunogenicity and Safety of BBIBP-CorV Vaccine in Adults in GuineaStatus: Active (not recruiting), Estimated PCD: 2023-08-03